Endocrine Abstracts

Background: SGLT2i have shown promising results as an adjunct therapy in T1DM, resulting in better glucose control, weight loss and lower blood pressure. No increase in hypoglycemia risk, in particular severe hypoglycemia, was observed, but, an mild increased risk of (euglycemic) diabetic DKA was reported (Van den Mooter L. et al. Exp Opinion Pharm 2018).Case report: A 49-year-old Caucasian female nurse with underlying type 1 diabetes was admitt...